Gynecologic Cancer

The Division of Gynecologic Oncology at Mount Sinai was founded in 1967 before the discipline even received official designation as a subspecialty of The American Board of Obstetrics and Gynecology. Since then, we've been at the forefront in the treatment of all gynecologic cancers — the most common type of cancer in women after breast, lung, and colon cancers.

Our services include cancer screening, early detection, therapy, and post-treatment surveillance. The cancers we treat include cancers of the:

• Cervix
• Fallopian tube
• Ovary
• Uterus
• Vagina
• Vulva

Treatments We Provide

We provide a comprehensive range of treatments for gynecologic malignancies and complex benign gynecologic conditions. These include:

• Laser and laparoscopic surgeries
• Lymphadenectomy
• Ovarian cytoreduction and debulking
• Port implantation
• Urologic and bowel surgery

Mount Sinai was an early adaptor of the new robotic surgical systems in place now — many years before the systems were considered acceptable by most centers. These minimally invasive surgeries provide shorter hospital stays, less scarring, and a faster return to normal activity. Approximately 60 percent of our surgeries are performed using a minimally invasive approach.

We take a multidisciplinary approach, using experts in diagnostic and interventional radiology, genetics, radiation therapy, palliative care, behavioral medicine, nutrition, and physical therapy.

Practicing at the Derald H. Ruttenberg Cancer Center and in collaboration with The Tisch Cancer Institute we manage surgical patients, provide consultations, and administer chemotherapy in a unified and intimate setting designed to ensure patient privacy and comfort. Our nurses are specifically trained in cancer treatment services and on-site oncology pharmacists.

As a member of the Gynecologic Oncology Group (GOG), our patients get exposure to national clinical trials for the treatment of gynecologic cancers. Mount Sinai physicians have been pioneers in investigating optimal chemotherapeutic regimens leading to significant improvements in outcomes. Current investigations and clinical trials are available for patients with ovarian, uterine, cervical, and endometrial cancers.

We also facilitate access to social services and internal support groups including Woman to Woman, a one-on-one support program for women facing gynecologic cancer and their families.

Gynecologic cancer is an illness that impacts the entire family. Receiving the diagnosis is a devastating and frightening experience for you and your family. By providing you and your family with information and support, we can help everyone cope with the reality of your diagnosis and enable your family members to become more effective caregivers and advocates.

Division Leadership

Linus Chuang, MD
Director, Gynecologic Oncology and Co-Director, Minimally Invasive Surgery
Associate Professor, Department of Obstetrics, Gynecology and Reproductive Medicine

Nimesh Nagarsheth, MD
Associate Director, Gynecologic Oncology
Associate Professor, Department of Obstetrics, Gynecology and Reproductive Science

David Fishman, MD
Fellowship Director, Gynecologic Oncology
Professor, Obstetrics, Gynecology and Reproductive Science